QSAR Based on Multiple Linear Regression and PLS Methods for the Anti-HIV Activity of a Large Group of HEPT Derivatives

Quantitative structure-activity relationships have been developed for a set of 107 inhibitors of the HIV-1 reverse transcriptase, derivatives of a recently reported HIV-1 specific lead: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). The activity of these compounds was investigated by means of multiple linear regression (MLR) and PLS regression techniques and topological indexes as well as several tabulated physicochemical substituent constants were used as predictor variables. The results obtained indicate that the anti-HIV activity of the HEPT derivatives is strongly dependent on hydrophobic factors as expressed by the Hansch constant (sigma pi (R1+R2)), and especially dependent on the geometric factors mainly accounted for by the 1 chi N (R2) and 4 chi pN molecular connectivity indexes and also for the molecular volume (Vx), the Taft steric constant (Es(2R1)), and the Verloop parameter for the smallest width value (B1(3R1)). Besides, for this data set, comparison of the quality of MLR and PLS models show that PLS is a better approach to MLR for improving the interpretability of the data and also to exhibit models with a better predictive quality.

[1]  S. Nesnow.  A preliminary structure-activity study of the mixed-function oxidase inhibitor 7,8-benzoflavone. , 1979, Journal of medicinal chemistry.

[2]  H. Mitsuya,et al.  Molecular targets for AIDS therapy. , 1990, Science.

[3]  M. Abraham,et al.  The use of characteristic volumes to measure cavity terms in reversed phase liquid chromatography , 1987 .

[4]  Erik De Clercq,et al.  The synthesis of novel 6-substituted acyclouridine derivatives which show specific inhibition of HIV-1 , 1990 .

[5]  J. Topliss,et al.  Chance factors in studies of quantitative structure-activity relationships. , 1979, Journal of medicinal chemistry.

[6]  Corwin Hansch,et al.  QSAR of HIV inhibitors , 1992 .

[7]  P E Wright,et al.  Structural characterization of a partly folded apomyoglobin intermediate. , 1990, Science.

[8]  Erik De Clercq,et al.  Lithiation of Uracilnucleosides and its Application to the Synthesis of a New Class of Anti-HIV-1 Acyclonucleosides , 1991 .

[9]  P. Halushka,et al.  Novel synthesis and biochemical properties of an [125I]-labeled photoaffinity probe for thromboxane A2/prostaglandin H2 receptors. , 1991, Journal of medicinal chemistry.

[10]  Michael H. Abraham,et al.  Scales of solute hydrogen-bonding: their construction and application to physicochemical and biochemical processes , 2010 .

[11]  R T Walker,et al.  A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. , 1989, Journal of medicinal chemistry.

[12]  S. Wold.  Cross-Validatory Estimation of the Number of Components in Factor and Principal Components Models , 1978 .

[13]  Richard T. Walker,et al.  Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. , 1996, Journal of medicinal chemistry.

[14]  Erik De Clercq,et al.  Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. , 1995 .

[15]  Erik De Clercq,et al.  Trends in drug development for the treatment of AIDS compounds interfering with the initial stages of the HIV replicative cycle , 1994 .

[16]  Supa Hannongbua,et al.  Structure-activity correlation study of HIV-1 inhibitors: Electronic and molecular parameters , 1996, J. Comput. Aided Mol. Des..

[17]  Erik De Clercq,et al.  Design and Synthesis of Regioisomeric Analogues of a Specific Anti-HIV-1 Agent 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) , 1994 .

[18]  C J Blankley,et al.  Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran-2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus. , 1991, Journal of medicinal chemistry.

[19]  J. Proudfoot,et al.  Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 5. 4-Substituted and 2,4-disubstituted analogs of nevirapine. , 1995, Journal of medicinal chemistry.

[20]  R T Walker,et al.  Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. , 1989, Biochemical and biophysical research communications.